Keywords
How to Cite
Abstract
IgG4-related disease (IgG4-RD) it is a clinicopathological entity recently described, with a broad spectrum of clinical manifestations that share a common histopathology. Arriving to diagnosis is difficult, requiring clinical, laboratory and histopathology complementary findings. Usually a good response is observed after treatment with steroids; however there are a few case reports of successful therapy with immunosupressors and B cell depletory drugs. This case report allows depicting the diagnosis challenge that this entitiy often entails.
References
2. Wallace ZS. An update on IgG4-related disease. Medical physiology and rheumatic disease. 2015; 27: 83-90.
3. Wallace ZS. Plasmablasts as biomarker for IgG4-related disease, independent of serum Ig4 concentrations. Ann Rheum Dis. 2014; 0:1-6.
4. Carruthers MN. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015; 0:1-7.
5. Stone JH. Diagnostic Approach to the complexity of IgG4-Related Disease. Mayo Clín Proc. 2015;90:927-939.
6. Stone JH. IgG4 Related-Disease. N Engl J Med. 2012;366: 539-551.
7. Masaki Y. IgG4-Related Disease: a novel lymphoproliferative disorder discovered and establish in Japan in the 21st century. J Clin Exp Hematopathol. 2011;51: 13-20.
8. Khosroshahi A. International Consensus Guidance Statement on the Management and Treatment of IgG4 Related Disease. Arthritis & Rheumatology. 2015; 67: 1688-1699.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar